Flushing events

Scharf MB, McDannold MD, Stover R, Zaretsky N, Berkowitz DV (1997) Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women a pilot study. Clin Ther 19 304—311... 

Short-term idling Short-term idling includes membranes that are off line for no more than 48 hours. An automatic flush event should occur at least once every 24 hours. No other steps need to be taken to preserve the membranes. 

The material should be stored in corrosion-resistant containers, away from alkaline or strong oxidizing materials. In the event of a spill or leak, nonsparking equipment should be used, and dusty conditions should be avoided. Spills should be covered with soda ash, then flushed to drain with large amounts of water (5). 

In the event of acid spilling on one s person, flush thoroughly with water immediately. Be aware that acid-water mixtures will produce heat. Removing clothing from the affected area while water flushing may be important, so as to not trap hot acid-water mixtures against the skin. Acids or acid-water mixtures can cause very serious burns if left in contact with skin, even if only for a very short period of time. 

When a mechanical seal is specified, it shall be located at the cover plate to seal the vapor in the supply tank or vessel. Mechanical seals normally seal vapor however, they shall be designed to operate in liquid in the event of tank or vessel overfilling. With purchaser approval, the vendor may supply a seal pressurized by flush from the pump discharge or from an external source. External seal flush must be compatible with the liquid being pumped. The seal chamber shall have provisions for a high point vent. 

Other adverse events may include pancytopenia, aplastic anemia, neutropenia, leukopenia, thrombocytopenia, lymphopenia, leukocytosis, lymphadenopathy, coagulation disturbances, hypotension/shock, heart failure, angina/MI, tachycardia, bradycardia, tachypnea/hyperventilation, abnormal chest sounds, pneumonia/pneumonitis, rash, urticaria, pruritus, erythema, flushing, diaphoresis, diarrhea, bowel infarction, arthralgia, arthritis, blindness, blurred vision, diplopia, hearing loss, otitis media, tinnitus, vertigo, photophobia, conjunctivitis, nasal/ear stuffiness, and anuria/oliguria. 

The most common reasons for discontinuation of treatment were infusion-related reactions (ie, dyspnea, flushing, headache, rash). Adverse events have been reported in a higher proportion of RA patients receiving the 10 mg/kg dose than the 3 mg/kg dose however, no differences were observed in the frequency of adverse events between the 5 and 10 mg/kg doses in patients with Crohn disease. 

Exemestane is known uniquely as an aromatase inactivator. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its irreversable inactivation. Exemestane is used for the treatment of hormonally-responsive breast cancer in postmenopausal women. It is generally well tolerated and adverse events are usually mild to moderate. Adverse events include hot flushes, nausea, fatigue and increased appetite. 

Adverse reactions to the administration of adenosine are fairly common however, the short half-life of the drug limits the duration of such events. The most common adverse effects are flushing, chest pain, and dyspnea. Adenosine may induce profound bronchospasm in patients with known reactive airway disease. The mechanism for bronchospasm is unclear, and the effect may last for up to 30 minutes despite the short half-life of the drug. 

---